NUCLEOLIN and cancer: Recently, AS1411 has been largely employed as a selective nucleolin-targeting agent, successfully combined with chemotherapeutic agents (such as paclitaxel [228,229,230,231], docetaxel [232,233,234], doxorubicin [235,236,237,238,239,240,241,242,243,244], and epirubicin) [245] onto suitable nanosystems in the context of specific recognition of cancer cells and tumour-selective delivery of therapeutic or imaging agents for cancer treatment [227].